Country: United States
Language: English
Source: NLM (National Library of Medicine)
MIGLITOL (UNII: 0V5436JAQW) (MIGLITOL - UNII:0V5436JAQW)
Sun Pharmaceutical Industries Inc.
Miglitol
Miglitol 25 mg
ORAL
PRESCRIPTION DRUG
Miglitol tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Miglitol tablets are contraindicated in patients with:
Miglitol tablets are available as 25 mg, 50 mg, and 100 mg white to off-white, circular, biconvex film-coated tablets, debossed with the logo-mark "OP" on one side and the product code on the other side, as indicated below. Strength NDC Tablet Identification Bottles of 100 : Front Back 25 mg 57664-684-88 OP 25 50 mg 57664-685-88 OP 26 100 mg 57664-686-88 OP 27 Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Manufactured by: Orient Pharma Co., Ltd. Yunlin, Taiwan Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Rev. 03/2015
Abbreviated New Drug Application
MIGLITOL- MIGLITOL TABLET, COATED SUN PHARMACEUTICAL INDUSTRIES INC. ---------- MIGLITOL TABLETS DESCRIPTION Miglitol Tablets, an oral alpha-glucosidase inhibitor for use in the management of non-insulin- dependent diabetes mellitus (NIDDM). Miglitol is a desoxynojirimycin derivative, and is chemically known as 3,4,5-piperidinetriol, 1-(2-hydroxyethyl) -2-(hydroxymethyl)-, [2R-(2a,3ß,4a, 5ß)]-. It is a white to pale-yellow powder with a molecular weight of 207.2. Miglitol is soluble in water and has a pKa of 5.9. Its empirical formula is C H NO and its chemical structure is as follows Miglitol tablets are available as 25 mg, 50 mg, and 100 mg tablets for oral use. The inactive ingredients are corn starch, microcrystalline cellulose, magnesium stearate, hypromelloses, polyethylene glycols, titanium dioxide, and polysorbate 80. CLINICAL PHARMACOLOGY Miglitol is a desoxynojirimycin derivative that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. As a consequence of plasma glucose reduction, miglitol tablets reduce levels of glycosylated hemoglobin in patients with Type II (non-insulin-dependent) diabetes mellitus. Systemic nonenzymatic protein glycosylation, as reflected by levels of glycosylated hemoglobin, is a function of average blood glucose concentration over time. MECHANISM OF ACTION In contrast to sulfonylureas, miglitol tablets do not enhance insulin secretion. The antihyperglycemic action of miglitol results from a reversible inhibition of membrane-bound intestinal α-glucoside hydrolase enzymes. Membrane-bound intestinal α-glucosidases hydrolyze oligosaccharides and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. In diabetic patients, this enzyme inhibition results in delayed glucose absorption and lowering of postprandial hyperglycemia. Because its mechanism of action is different, the effect of miglitol tablets to enhance glycemic control is additive to that of sulfonylure Read the complete document